Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably
combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of
improved anticancer immunotherapy. It will focus on three key cancers, all in clear need of
improved therapies - NSCLC, pancreatic cancer and mesothelioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborators:
Cancer Research UK Merck Sharp & Dohme Corp. Queen's University, Belfast University of Edinburgh University of Glasgow University of Leicester University of Southampton Verastem, Inc.